A Narrative Review on Axonal Neuroprotection in Multiple Sclerosis-Reference-Cited by-同舟云学术

A Narrative Review on Axonal Neuroprotection in Multiple Sclerosis

Published:2022-05-24 Issue:3 Volume:11 Page:981-1042
ISSN:2193-8253
Container-title:Neurology and Therapy
language:en
Short-container-title:Neurol Ther

Author:

Collongues Nicolas^ORCID,Becker Guillaume,Jolivel Valérie,Ayme-Dietrich Estelle,de Seze Jérôme,Binamé Fabien,Patte-Mensah Christine,Monassier Laurent,Mensah-Nyagan Ayikoé Guy

Publisher

Springer Science and Business Media LLC

Subject

Neurology (clinical),Neurology

Link

https://link.springer.com/content/pdf/10.1007/s40120-022-00363-7.pdf

Reference374 articles.

1. Reich DS, Lucchinetti CF, Calabresi PA. Multiple sclerosis. N Engl J Med. 2018;378:169–80. https://doi.org/10.1056/NEJMra1401483.

2. Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17:162–73. https://doi.org/10.1016/S1474-4422(17)30470-2.

3. Confavreux C, Vukusic S. Natural history of multiple sclerosis: a unifying concept. Brain. 2006;129:606–16. https://doi.org/10.1093/brain/awl007.

4. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology. 1996;46:907–11. https://doi.org/10.1212/wnl.46.4.907.

5. Brown JWL, Coles A, Horakova D, et al. Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis. JAMA. 2019;321:175–87. https://doi.org/10.1001/jama.2018.20588.

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Life history of a brain autoreactive T cell: From thymus through intestine to blood-brain barrier and brain lesion;Neurotherapeutics;2024-09

2. Minocycline as a prospective therapeutic agent for cancer and non-cancer diseases: a scoping review;Naunyn-Schmiedeberg's Archives of Pharmacology;2023-11-22

3. Therapeutic Plasma Exchange and Multiple Sclerosis Dysregulations: Focus on the Removal of Pathogenic Circulatory Factors and Altering Nerve Growth Factor and Sphingosine-1-Phosphate Plasma Levels;Current Issues in Molecular Biology;2023-09-25

4. The therapeutic value of treatment for multiple sclerosis: analysis of health technology assessments of three European countries;Frontiers in Pharmacology;2023-04-28

5. Evaluation and management of acute high-grade immunotherapy-related neurotoxicity;Heliyon;2023-03